Home › All Companies › ACTU › Current Report

ACTUATE THERAPEUTICS, INC. (ACTU) — Current Report

AI-Powered SEC Filing Analysis

← All ACTU filings
Latest Current Report Filed: 2026-01-12

Key Insights

  • Actuate Therapeutics, Inc. announced updated data from its ongoing Phase 2 trial of elraglusib in combination with gemcitabine/nab-paclitaxel for the treatment of metastatic pancreatic ductal adenocarcinoma (mPDAC), a potentially significant development for the company's pipeline.
  • The company is an emerging growth biotech, which may indicate higher risk and volatility for investors compared to more established pharmaceutical firms.
  • Investors should closely monitor the progress of the Phase 2 trial and any future regulatory updates, as the success or failure of this drug candidate could have a material impact on the company's valuation and stock price.
Sentiment: Positive Significance: 7/10
View Original Filing →

Want the newest filings?

This analysis covers the filing from 2026-01-12. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Other reports for ACTUATE THERAPEUTICS, INC.

Insider Trading Annual Report

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.